Table 1

 Baseline characteristics of patients

CharacteristicsKnee OA (n = 603)Hip OA (n = 211)
*Non-steroidal anti-inflammatory drugs (before the start of the study); †other than NSAIDs (before the start of the study); ‡chondroitin sulphate, diacerhein, or avocado/soybean unsaponifiables.
Age (years)67.910.264.610.2
Weight (kg)75.513.871.312.3
Height (cm)163.88.5164.78.4
Body mass index (kg/m2)28.14.826.23.8
Disease duration (years)
Pain score (0–100 mm VAS)
    Week 059.316.256.716.5
    Change (week 0–week 4)−24.921.5−20.021.7
Patient global assessment (0–100 mm VAS)
    Week 059.618.358.019.3
    Change (week 0–week 4)−24.724.0−20.623.2
WOMAC function score (0–100)
    Week 042.816.144.416.5
    Change (week 0–week 4)−11.613.9−10.413.6
No % No %
Female sex42169.813363.0
Kellgren & Lawrence grade
NSAID* intake during past 4 weeks17829.76932.7
Analgesic treatment**34457.214.167.1
Symptomatic slow-acting drug intake***20934.89042.9